Life sciences toolmaker Danaher (DHR) reported better-than-expected financial results for the first quarter of 2024. Despite an 18% decline in its Biotechnology division, the company’s Life Sciences and Diagnostics divisions recorded growth, resulting in a 3% overall revenue decline compared to the same period last year. The company also reported strong operating cash flow. Danaher’s competitors, such as Repligen, Bio-Rad, and Thermo Fisher Scientific, are expected to be closely watched in light of these positive results.